Skip to content
Yog Pharma
Central nervous systemAcetylcholinesterase inhibitor

Donepezil Hydrochloride is an acetylcholinesterase inhibitor indicated for dementia of the Alzheimer's type. We supply it to US manufacturers of tablets and orally disintegrating tablets.

CAS120011-70-3416.0 g/molC24H30ClNO3
2D structure of Donepezil Hydrochloride, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 5741) and FDA’s substance registry

CAS number

120011-70-3

Molecular formula

C24H30ClNO3

Molecular weight

416.0g/mol

FDA UNII

IUPAC name

2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one;hydrochloride

InChIKey

XWAIAVWHZJNZQQ-UHFFFAOYSA-N

Appearance
White to off-white powder.
Solubility
Freely soluble in chloroform, soluble in water and glacial acetic acid, slightly soluble in ethanol and acetonitrile, and practically insoluble in ethyl acetate and n-hexane.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Exists in several polymorphic and hydrated forms. State the form, since sources file them separately.

On the US market

Reference product
AriceptNDA 020690
Approved ANDAs
22 with a marketed product
Approved forms and strengths
  • Tablet 5 mg, 10 mg, 23 mg
  • Orally disintegrating tablet 5 mg, 10 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com